Skip to main content
Premium Trial:

Request an Annual Quote

NorayBio Licenses Noraymet to BioDynamics

NEW YORK, July 20 (GenomeWeb News) - NorayBio licensed its biopharmaceutical platform to BioDynamics, NorayBio said today.

 

The platform, Noraymet ADME, predicts human pharmacokinetic models of new compounds from in vitro ADME data.

 

NorayBio has licensed the product to Spain's Faes Farma and Finland's Novamass.

 

NorayBio and BioDynamics also plan to co-develop software based on Noraymet ADME to refine human pharmacokinetic modelling.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.